Brind.

Revolution Medicines submitted data for elironrasib, a clinical-stage drug, for review by the FDA for treating Non-Small Cell Lung Cancer.

7 reports, 2 independent Updated Sep 11

Gone quiet

Reports: 7
Developments: 1
Repetition: 86%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Revolution Medicines submitted data for elironrasib, a clinical-stage drug, for review by the FDA for treating Non-Small Cell Lung Cancer.

Who's involved

What this event is mainly about

Revolution Medicines (United States)FDA

Keep exploring

The entities involved

Revolution Medicines (United States)
company in Redwood City, United States

Nothing else this week.
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

daraxonrasib received Breakthrough Therapy Designation from the FDA for metastatic pancreatic ductal adenocarcinoma.Jun 8

Coverage

Newest first; wire copies grouped

Aug 26cnn.com
Aug 14Insider MonkeyRevolution Medicines Receives FDA Breakthrough Therapy Designation for Elironrasib for Lung Cancer Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best upside stocks to invest in now. Earlier o

5 more outlets ran the same wire story